ArticleCardiovascular & hematological disorders drug targets2022
In vivo Antihyperglycemic and Antidyslipidemic Effects of L-Tartaric Acid.
Article in Cardiovascular & hematological disorders drug targets, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 8 citations in OpenAlex.
- The effects of L-tartaric acid on diabetic cataracts through modulation of oxidative stress and inflammation in diabetic rats.BMC ophthalmology · 2025Article
- Comprehensive Evaluation of the Effects of Hot Air Drying Temperature on the Chemical Composition, Flavor Characteristics and Biological Activity ofFoods (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
aimsThe aim of the study was to investigate the antihyperglycemic effect of L-Tartaric acid.
backgroundL-Tartaric acid is a natural product with possible beneficial effects on health.
objectiveThe goal of this work was to evaluate the antihyperglycemic and antidyslipidemic effects of L-Tartaric acid (L-TA) in rats. MATERIALS AND
methodsIn the first model, the effects of L-TA (10 and 40 mg/kg) on diabetes conditions induced by streptozotocin (STZ) in rats were investigated. In the second model, the effects of L-TA (40 and 80 mg/kg) on dyslipidemia induced by tyloxapol (Triton WR-1339) in rats were assessed.
resultsL-TA (40 mg/kg) had improved all studied parameters. L-TA at 40 mg/kg was able to significantly reduce glycaemia, improve oral glucose tolerance (OGT), increase glycogen content in liver and extensor digitorum longus (EDL) muscle, and ameliorate the lipidic profile and atherogenic indices in STZ-diabetic rats.
conclusionL-Tartaric acid was able to exhibit antihyperglycemic and antidyslipidemic effects in STZ-induced diabetic rats. Moreover, the antidyslipidemic effect of L-Tartaric acid was confirmed in tyloxapol-induced hyperlipidemic rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.